KR20000052806A - 인털루킨 유전자의 발현을 억제하는 올리고머 - Google Patents

인털루킨 유전자의 발현을 억제하는 올리고머 Download PDF

Info

Publication number
KR20000052806A
KR20000052806A KR1019990703625A KR19997003625A KR20000052806A KR 20000052806 A KR20000052806 A KR 20000052806A KR 1019990703625 A KR1019990703625 A KR 1019990703625A KR 19997003625 A KR19997003625 A KR 19997003625A KR 20000052806 A KR20000052806 A KR 20000052806A
Authority
KR
South Korea
Prior art keywords
oligonucleotide
group
polypurine
seq
oligomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019990703625A
Other languages
English (en)
Korean (ko)
Inventor
비어래퍼네인데인지
하마나카쇼지
노자와이와오
Original Assignee
히사미츠 파머수티컬 컴퍼니 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 히사미츠 파머수티컬 컴퍼니 인코포레이티드 filed Critical 히사미츠 파머수티컬 컴퍼니 인코포레이티드
Publication of KR20000052806A publication Critical patent/KR20000052806A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019990703625A 1996-10-25 1997-08-29 인털루킨 유전자의 발현을 억제하는 올리고머 Ceased KR20000052806A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/740,215 US5874566A (en) 1996-10-25 1996-10-25 Il-15 triplex oligonucleotides
US8/740,215 1996-10-25

Publications (1)

Publication Number Publication Date
KR20000052806A true KR20000052806A (ko) 2000-08-25

Family

ID=24975523

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019990703625A Ceased KR20000052806A (ko) 1996-10-25 1997-08-29 인털루킨 유전자의 발현을 억제하는 올리고머

Country Status (7)

Country Link
US (1) US5874566A (https=)
EP (1) EP0937099A4 (https=)
JP (1) JP2001503620A (https=)
KR (1) KR20000052806A (https=)
AU (1) AU720110B2 (https=)
CA (1) CA2269722A1 (https=)
WO (1) WO1998018812A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192935B1 (en) 1993-03-08 2007-03-20 Amgen Inc. Polynucleotides encoding epithelium-derived T-cell factor and uses thereof
US6087172A (en) * 1997-10-31 2000-07-11 Hisamitsu Pharmaceutical Co., Inc. Ribozymes targeted to human IL-15 mRNA
IL126919A0 (en) * 1998-11-05 1999-09-22 Univ Ben Gurion Antisense oligomer
JP2002519439A (ja) * 1998-07-07 2002-07-02 久光製薬株式会社 Ｉｌ−１５に標的されたアンチセンスオリゴヌクレオチド
US5985663A (en) * 1998-11-25 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of interleukin-15 expression
GB9910119D0 (en) * 1999-04-30 1999-06-30 Novartis Ag Organic compounds
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
EP1326892A2 (en) 2000-10-12 2003-07-16 University of Rochester Compositions that inhibit proliferation of cancer cells
US7049069B2 (en) 2001-07-17 2006-05-23 University Of Florida Detecting and treating reproductive tract disorders
WO2003065997A2 (en) 2002-02-06 2003-08-14 Vicor Technologies, Inc. Anti-infarction molecules
AU2003253580A1 (en) * 2002-02-26 2003-11-17 University Of Minnesota Variants of nedd4l associated with hypertension and viral budding
EP1575992A4 (en) 2002-08-05 2007-02-21 Univ Rochester CHEMICAL PROTEINS FROM PROTEIN TRANSDUCATING DOMAIN / DEAMINASE, RELATED COMPOUNDS AND THEIR USES
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
US7476733B2 (en) * 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
WO2007044607A2 (en) * 2005-10-06 2007-04-19 Emthrax, Llc Methods and compositions relating to anthrax spore glycoproteins as vaccines
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP2392645A1 (en) 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
EP2560001B1 (en) 2006-09-21 2016-04-13 University of Rochester Compositions and methods related to protein displacement therapy for myotonic distrophy
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
BRPI0720038A2 (pt) 2006-12-11 2013-12-24 Univ Utah Res Found Métodos para inibir a permeabilidade vascular em tecido, para triar ou avaliar um agente que inibe a permeabilidade vascular, para tratar ou prevenir a síndrome da angústia respiratória, a retinopatia de prematuridade, a retinopatia diabética e a degeneração macular úmida em um indivíduo, para tratar indivíduos com sugestões repulsivas ou miméticos e para promover a angiogênese em um tecido, polipeptídeo isolado, ácido nucleico isolado, e, vetor
WO2009026496A1 (en) * 2007-08-22 2009-02-26 University Of Southern California Grp78 and tumor angiogenesis
WO2009032702A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
EP2195331B1 (en) * 2007-08-28 2013-11-20 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
WO2010070380A2 (en) 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Doc1 compositions and methods for treating cancer
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
US20110262395A1 (en) 2008-05-08 2011-10-27 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
US20100286762A1 (en) * 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
WO2011031974A1 (en) 2009-09-10 2011-03-17 Southern Research Institute Acridine analogs in the treatment of gliomas
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
CN103608680A (zh) 2010-12-14 2014-02-26 詹姆士·W·里拉尔德 抗cxcl13抗体和抗cxcr5抗体在恶性肿瘤的治疗或检测中的用途
WO2014093688A1 (en) 2012-12-12 2014-06-19 1Massachusetts Institute Of Technology Compositions and methods for functional nucleic acid delivery
EP3071590A4 (en) 2013-11-21 2017-07-19 SeNA Research, Inc. Methods for structural determination of selenium derivatized nucleic acid complexes
WO2016018665A1 (en) 2014-07-31 2016-02-04 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
US10723794B2 (en) 2015-03-18 2020-07-28 University Of South Carolina Anti-CcL8 antibodies and uses thereof
CN110087665A (zh) 2016-08-03 2019-08-02 H·李·莫菲特癌症中心与研究所公司 Tlr9靶向治疗
US12016314B2 (en) 2017-09-08 2024-06-25 Ohio State Innovation Foundation MicroRNA inhibitor therapy in systemic lupus erythematosus
EP4284513A1 (en) 2021-01-26 2023-12-06 Universite Brest Bretagne Occidentale Novel stim1 splicing variants and uses thereof
US12492245B2 (en) 2021-09-21 2025-12-09 University Of South Carolina Anti-CCL8 antibodies and treatment of lung injury by CCL8 inhibition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15

Also Published As

Publication number Publication date
US5874566A (en) 1999-02-23
EP0937099A1 (en) 1999-08-25
AU4331497A (en) 1998-05-22
JP2001503620A (ja) 2001-03-21
AU720110B2 (en) 2000-05-25
CA2269722A1 (en) 1998-05-07
EP0937099A4 (en) 2005-01-19
WO1998018812A1 (en) 1998-05-07

Similar Documents

Publication Publication Date Title
KR20000052806A (ko) 인털루킨 유전자의 발현을 억제하는 올리고머
US5650316A (en) Uses of triplex forming oligonucleotides for the treatment of human diseases
US7667027B2 (en) Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-β (TGF-β)
EP0703979B1 (en) Method for treating kaposi's sarcoma with antisense oligonucleotides
KR101107818B1 (ko) 향상된 면역자극 효능을 가진 ｃ-부류 올리고뉴클레오티드유사체
Yamamoto et al. Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length
WO1998014615A1 (en) Antisense oligonucleotide modulation of mdr p-glycoprotein gene expression
WO2017007886A2 (en) Compositions for inhibiting dux4 gene expression and uses thereof
EP0695354B1 (en) Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta1 (tgf-beta1)
US20070093439A1 (en) Short immunomodulatory oligonucleotides
US7662792B2 (en) Modulation of Fas and FasL expression
KR100199247B1 (ko) Ras 유전자의 안티센스 올리고뉴클레오티드 저해
WO1996040157A1 (en) USE OF ANTISENSE OLIGONUCLEOTIDES TO IL-6 RECEPTOR mRNA TO INHIBIT CELLULAR PROLIFERATION
JP2026510985A (ja) 環状プロドラッグ核酸を使用したｒｎａ治療薬の送達
McMahon et al. Intraperitoneal injection of antisense peptide nucleic acids targeted to the mu receptor decreases response to morphine and receptor protein levels in rat brain
Khaled et al. Inhibition of the p50 (NFκB1) subunit of NF-κB by phosphorothioate-modified antisense oligodeoxynucleotides reduces NF-κB expression and immunoglobulin synthesis in murine B cells
US5716846A (en) Method for inhibiting cellular proliferation using antisense oligonucleotides to interleukin-6 receptor mRNA
AU705122B2 (en) Oligonucleotides specific for cytokine signal transducer gp130 mRNA
US5674995A (en) Oligonucleotides specific for cytokine signal transducer gp130 mRNA
WO1998040478A2 (en) Antisense inhibition of human stat-6
WO1996035705A1 (en) Inhibition of transcription factor-mediated transcriptional activation by oligomer strand invasion
WO1995032628A1 (en) Oligonucleotide inhibitors of cytokine production and tumors responsive to cytokines
Morassutti et al. Effect of phosphorothioate modifications on the ability of GTn oligodeoxynucleotides to specifically recognize single-stranded DNA-binding proteins and to affect human cancer cellular growth
WO2007050059A2 (en) Short immunolomodulatory oligonucleotides
Bhan et al. Inhibition of 5-α-Reductase (TYPE-II) Expression by Antisense 3′-Deoxy-(2′-5′) Oligonucleotide Chimeras

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19990424

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20020822

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20041130

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20050222

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20041130

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I